Denise A. Yardley, MD

Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, on the treatment of patients with breast cancer with bone health issues.

Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.

Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the role of Afinitor (everolimus) in breast cancer and the BOLERO trials.

Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.